Loading
A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) is a phase 3 interventional study registered as NCT06051409 by Ascentage Pharma Group Inc., with 350 participants planned, started 2023-08-31. Conditions listed: Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Olverembatinib, Ascentage Pharma, Small-molecule kinase inhibitors.
Shares Olverembatinib, Ascentage Pharma, Small-molecule kinase inhibitors.
Shares Olverembatinib, Ascentage Pharma.
Shares Olverembatinib, Ascentage Pharma, Acute lymphoblastic leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/